For US Healthcare Professionals Only
Hear from a renowned expert on how VUITY™ may benefit your patients.
VUITY™ (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.
VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.
Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.
Rare cases of retinal detachment have been reported with other miotics when used in susceptible patients and those with pre-existing retinal disease. Patients should be advised to seek immediate medical care with sudden onset of vision loss.
VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.
Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.
To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.
The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia.
Please see full Prescribing Information.
US-PBY-210241
Reference: 1. VUITY Prescribing Information.
